



PubMed Nucleotide Protein Genome Structure PopSet Taxonomy OMIM Bo

Search PubMed for Limits Preview/Index History Clipboard Details

About Entrez

Display Abstract Sort Save Text Clip Add Order

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy

PubMed Services
Journal Browser
MeSH Browser
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Privacy Policy

1: Curr Opin Pharmacol 2001 Jun;1(3):265-71

Related Articles. **NEW Books.**
LinkOut

Monoclonal antibodies as a strategy for pulmonary diseases.

Torphy TJ, Li L, Griswold DE.

Centocor Inc., Malvern, PA 19355-1307, USA. torphyt@centocor.com

Monoclonal antibodies have been used successfully to elucidate the roles of putative mediators of pulmonary disease. In particular, clinical trials with monoclonal antibodies directed against interleukin-5, IgE or CD4 yielded results that were critical in dissecting the pathophysiology of asthma; but, more importantly, fundamental changes in the discovery, manufacture and safety of monoclonal antibodies have reinforced the enormous potential of these agents in treating pulmonary diseases. An unprecedented number of monoclonal antibodies are in development for a variety of acute and chronic conditions. Moreover, whereas only two monoclonal antibodies had received regulatory approval from the United States Food and Drug Administration between 1986 and 1997, seven more have received approval since then. Indeed, monoclonal antibody therapy has come of age.

PMID: 11712750 [PubMed - in process]

Display Abstract Sort Save Text Clip Add Order

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer

spare-sun-solar.s2 6 Jan 29 2002 15:20:39